Understanding antibody changes in hemophilia A patients treated with emicizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the dynamics of antibodies and inhibitors against coagulation factor VIII in patients with severe hemophilia A who are receiving emicizumab therapy. The study will analyze leftover samples from routine care visits, allowing researchers to monitor changes without requiring additional procedures or visits from participants. By focusing on patients already undergoing treatment, the study seeks to provide insights into the immune response associated with emicizumab.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Severe congenital hemophilia A (CHA)
* Treatment with emicizumab irrespective of any other treatment
* Informed consent

Exclusion Criteria:

* No therapy with emicizumab
* Immunosuppressive therapy
* HIV-infection with CD4 (cluster of differentiation 4) cells \<200/µl

Where it's running

• University Hospital Frankfurt, Goethe University
  Frankfurt am Main, Hesse, Germany Recruiting

Study contacts

• Principal investigator: Christoph Koenigs, PD Dr. Dr — Goethe University
• Study coordinator: Stephan Schultze-Strasser, Dr.
• Email: stephan.schultze-strasser@kgu.de
• Phone: +496963016998

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Switching from Emicizumab to Marstacimab in Severe Hemophilia A

  This study is testing if switching from emicizumab to marstacimab is safe and how well the body handles the new medication in people with severe hemophilia A.

  Recruiting at 7 sites Phase 1 Pfizer · La Jolla, California and 9 other locations · NCT06703606

• Using Nuwiq to manage bleeding in hemophilia A patients during major surgery

  This study is testing if Nuwiq can help prevent bleeding during major surgery for boys and men over 12 with severe hemophilia A who are already using another treatment called emicizumab.

  Recruiting at 17 sites Phase 4 Octapharma · Dallas, Texas and 17 other locations · NCT05935358

• NXT007 versus emicizumab to prevent bleeds in people with Hemophilia A

  This will test whether NXT007 prevents bleeding better than emicizumab in people aged 12 and older with Hemophilia A, including those with or without factor VIII inhibitors.

  Recruiting at 63 sites Phase 3 Hoffmann-La Roche · Orange, California and 62 other locations · NCT07416604

• Emicizumab prophylaxis for people with Type 3 von Willebrand disease

  This trial will test whether regular emicizumab injections reduce bleeds compared with on-demand standard therapy for people aged 1 month and older with Type 3 von Willebrand disease, while also studying people already on prophylaxis using their prior data.

  Recruiting at 29 sites Phase 3 Hoffmann-La Roche · Sacramento, California and 28 other locations · NCT06998524

• Testing fitusiran to prevent bleeds in severe hemophilia A patients switching from emicizumab

  This study is testing if fitusiran can help prevent bleeding in men with severe hemophilia A who are switching from another treatment called emicizumab.

  Recruiting at 3 sites Phase 4 Sanofi · Los Angeles, California and 2 other locations · NCT06145373

• Evaluating the effects of a treatment on bone health in patients with severe hemophilia A

  This study is testing how a new treatment for severe hemophilia A affects bone and joint health over time to help make monitoring easier for patients.

  Recruiting Tri-Service General Hospital (TSGH) · Taipei, Neihu Dist. · NCT05981274

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.